Grifols (GRF) AI Stock Analysis

• Market Cap: €5.93B
• Dividend Yield: 0.83%
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): 14.9
• Beta (1Y): 0.82
• Revenue Growth: -0.33%
• EPS Growth: 51.93%
• Country: ES
• Employees: 25,000
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.67
• Shares Outstanding: 426,129,800
• 10 Day Avg. Volume: 1,216,950
• 30 Day Avg. Volume: 1,090,725
• PEG Ratio: 0.12
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 0.98
• P/FCF Ratio: 11.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €10.00
• Price Target Upside: 3.52% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.83
• Revenue Forecast (FY): €7.64B

• Rating: 60 Neutral
• Price Target: €11.00 ▲(13.87% Upside)
• Action: Reiterated
• Date: 07/30/26

Positive Factors

Vertical integration & plasma collection network

Grifols' integrated model — operating its own plasma donation/collection centers through to fractionation and commercialization — secures raw-material supply, reduces input-price exposure and strengthens margins. This vertical control supports long-term product availability, cost management and competitive barriers across geographies and therapies.

Negative Factors

Elevated leverage

High debt-to-equity increases refinancing and interest-rate vulnerability, constraining strategic flexibility. Sustained leverage at ~1.7–1.8x raises the cost of capital, limits capacity for bolt-on M&A or aggressive capex, and means operating shocks or revenue dips could materially pressure earnings and cash available for deleveraging.

Grifols Business Overview & Revenue Model

Company Description

Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from...

Read more

Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from...

How the Company Makes Money

Grifols makes money primarily by developing, manufacturing, and selling biologic medicines derived from human plasma. A core driver of its business model is vertical integration: it sources a significant portion of its key raw material by operatin...

Read more

Grifols makes money primarily by developing, manufacturing, and selling biologic medicines derived from human plasma. A core driver of its business model is vertical integration: it sources a significant portion of its key raw material by operatin...

Grifols Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.42B	7.52B	7.21B	6.59B	6.06B	4.93B
Gross Profit	2.76B	2.69B	2.85B	2.49B	2.23B	1.96B
EBITDA	1.62B	1.69B	1.61B	1.18B	1.21B	944.03M
Net Income	452.11M	401.89M	156.92M	59.31M	208.28M	265.33M
Balance Sheet
Total Assets	20.09B	19.71B	21.41B	21.44B	21.53B	19.23B
Cash, Cash Equivalents and Short-Term Investments	529.00M	825.49M	1.00B	645.72M	591.24M	2.68B
Total Debt	8.52B	9.57B	10.09B	10.12B	9.75B	9.32B
Total Liabilities	12.11B	12.11B	12.80B	13.47B	13.08B	11.09B
Stockholders Equity	5.55B	5.27B	5.88B	5.83B	6.13B	6.10B
Cash Flow
Free Cash Flow	766.66M	624.00M	669.63M	-87.14M	-386.43M	281.89M
Operating Cash Flow	1.09B	1.05B	902.17M	208.28M	-10.87M	596.98M
Investing Cash Flow	-520.00M	-579.00M	886.67M	-397.64M	-1.98B	-29.39M
Financing Cash Flow	-638.94M	-529.00M	-1.36B	186.04M	-173.49M	1.47B

Grifols Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:GRF, the sentiment is Positive. The current price of 9.66 is above the 20-day moving average (MA) of 9.64, above the 50-day MA of 9.24, and below the 200-day MA of 9.92, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 62.34 is Neutral, neither overbought nor oversold. The STOCH value of 49.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:GRF.

Grifols Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROVI	70 Outperform	€2.96B	16.17	27.84%	1.63%	3.21%	39.34%
ALM	62 Neutral	€2.42B	33.50	4.78%	1.63%	12.41%	342.01%
GRF	60 Neutral	€5.93B	14.87	8.43%	0.85%	-0.33%	51.93%
FAE	58 Neutral	€1.42B	13.74	18.19%	4.89%	31.88%	-20.09%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
RJF	51 Neutral	€219.01M	49.26	2.01%	0.74%	-3.23%	-60.06%